02-06-2026 17:06 via drugs.com

Sacituzumab Govitecan Shows Encouraging Results for Aggressive Endometrial Cancer

TUESDAY, June 2, 2026 -- A Trop-2-directed antibody-drug conjugate, sacituzumab govitecan (SG), demonstrates encouraging efficacy in a pretreated population with aggressive recurrent endometrial cancer (EC), according to a study published online May...

ASCO: Tile-Based Radiation Beneficial for Newly Resectable Brain Mets

ASCO: Apalutamide + ADT Beneficial in High-Risk Localized Prostate Cancer

Wearable Ultrasound Patch Provides Continuous Fetal Monitoring

Cardiometabolic Genetics Linked to Cognitive-Related Outcomes

Dose Reduction of Biologics Effective, Safe for Psoriasis

High Prevalence of Clinical Obesity Seen Even With Normal BMI

FDA Approves First Treatment for Chronic Hepatitis Delta Virus Infection

ASCO: Lower Incidence of Breast Cancer Seen With GLP-1 Receptor Agonist Exposure

ASCO: First-Line Sunvozertinib Beats Chemo for Advanced NSCLC

Patients From Most Rural Counties Have Worse Epilepsy Outcomes

2024 Saw Parkinson Disease Death Rate of 72 Per 100,000 Adults Aged 65 and Older

Resistance Training Tied to Lower Risk for Death Across Causes

Gut Microbial, Metabolomic Alterations Persist After Adenoma Resection

Cumulative Attrition for Surgeons 9.7 Percent Over Eight Years

Desktop versie

Sacituzumab Govitecan Shows Encouraging Results for Aggressive Endometrial Cancer

Pharmaceutical Industry news